Pharmacokinetics/pharmacodynamics of lefamulin in a neutropenic murine pneumonia model with Staphylococcus aureus and Streptococcus pneumoniae

In vivo pharmacodynamics of lefamulin, the first systemic pleuromutilin for human use, in a neutropenic murine thigh infection model

(2019) Wolfgang W Wicha et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens

(2018) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The effect of pulmonary surfactant on the in vitro activity of Iclaprim against common respiratory bacterial pathogens

(2018) David B. Huang et al.   DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE

Staphylococcus aureusCommunity-acquired Pneumonia: Prevalence, Clinical Characteristics, and Outcomes

(2016) Wesley H. Self et al.   CLINICAL INFECTIOUS DISEASES

Simultaneous assessment of the pharmacokinetics of a pleuromutilin, lefamulin, in plasma, soft tissues and pulmonary epithelial lining fluid

(2016) M. Zeitlinger et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

A novel pleuromutilin antibacterial compound, its binding mode and selectivity mechanism

(2016) Zohar Eyal et al.   Scientific Reports

Microbiological interaction studies between ceftazidime-avibactam and pulmonary surfactant and between ceftazidime-avibactam and antibacterial agents of other classes

(2014) John Dallow et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Penetration of GSK1322322 into Epithelial Lining Fluid and Alveolar Macrophages as Determined by Bronchoalveolar Lavage

(2013) Odin J. Naderer et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of Pulmonary Surfactant on Antimicrobial ActivityIn Vitro

(2013) R. Schwameis et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial Activity of the Pleuromutilin Antibiotic BC-3781 against Bacterial Pathogens Isolated in the SENTRY Antimicrobial Surveillance Program in 2010

(2013) Susanne Paukner et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

PK/PD models in antibacterial development

(2013) Tony Velkov et al.   CURRENT OPINION IN MICROBIOLOGY

Antimicrobial Activity of the Investigational Pleuromutilin Compound BC-3781 Tested against Gram-Positive Organisms Commonly Associated with Acute Bacterial Skin and Skin Structure Infections

(2012) Helio S. Sader et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs)

(2012) H. S. Sader et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Antimicrobial Properties of MX-2401, an Expanded-Spectrum Lipopeptide Active in the Presence of Lung Surfactant

(2011) Dominique Dugourd et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Pharmacokinetic‐Pharmacodynamic Considerations in the Design of Hospital‐Acquired or Ventilator‐Associated Bacterial Pneumonia Studies: Look before You Leap!

(2010) Paul G. Ambrose et al.   CLINICAL INFECTIOUS DISEASES

Cellular Accumulation and Pharmacodynamic Evaluation of the Intracellular Activity of CEM-101, a Novel Fluoroketolide, against Staphylococcus aureus, Listeria monocytogenes, and Legionella pneumophila in Human THP-1 Macrophages

(2009) S. Lemaire et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY